Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.